Investors

 

Key to long-term value: discipline, execution and consistent communication.

Print pageEmail pageShare page

News releases

The news releases listed below were believed to be accurate in all material respects at the time of original issuance. Please note that we do not intend, and assume no obligation, to update, correct, or otherwise modify any of these press releases for events that occur subsequent to the original release date. We suggest you review the more recent press releases in order to receive the most current information made available by ARIAD.

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
04/28/17Takeda Announces FDA Accelerated Approval of ALUNBRIG™ (brigatinib)
− ALUNBRIG Approved for ALK+ Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Progressed on or are Intolerant to Crizotinib – Cambridge, Mass. and Osaka, Japan – April 28, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that ALUNBRIG™ (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC... 
Printer Friendly Version
02/16/17Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.
– Significantly Enhances Takeda’s Global Oncology Portfolio – – Accretive to FY2018 Underlying Core Earnings – – Reinforces Takeda’s Commitment to Developing Medicines for Patients Living with Cancer – Cambridge, Mass. and Osaka, Japan, February 16, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) (“ARIAD”) for $24.00 per share in cash. “We are very pleased to have complet... 
Printer Friendly Version
02/06/17ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2017-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the submission of a Marketing Authorization Application (MAA) for its investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the European Medicines Agency (EMA). ARIAD is seeking marketing approval in the European Union of brigatinib in adult patients with anaplastic lymphoma kinase (ALK+) non-small cell lung cancer... 
Printer Friendly Version
01/09/17ARIAD Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion
ARIAD Stockholders to Receive $24.00 per Share in Cash CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2017-- ARIAD Pharmaceuticals (NASDAQ:ARIA) (“ARIAD”) today announced it has entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or a total enterprise value of approximately $5.2 billion, ... 
Printer Friendly Version
01/09/17Takeda to Acquire ARIAD Pharmaceuticals, Inc.
– Significantly Enhances Takeda’s Global Oncology Portfolio – – Accretive to FY2018 Underlying Core Earnings – – Reinforces Takeda’s Commitment to Developing Medicines for Patients Living with Cancer – Strategic Highlights Highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and reinforcing existing strength in hematology ... 
Printer Friendly Version
01/03/17ARIAD to Present at the 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2017-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business on Monday, January 9, 2017 at 4:30 p.m. (PT). The ARIAD presentation will be webca... 
Printer Friendly Version